Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-04. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Gram-positive cocci (Staphylococcus aureus, Streptococcus pyogenes, and Enterococci) Gram-negative rods (Escherichia coli, Pseudomonas aeruginosa, Klebsiella species, Bacteroides species, Prevotella species) Clostridium species (Clostridium perfringens, Clostridium septicum, and Clostridium sordellii) In polymicrobial (mixed) infections, Group A Streptococcus (S. pyogenes) is the most commonly found bacterium, followed by S. aureus. However, when the infection is caused solely by S. pyogenes and/or S. aureus, it is classified as a Type II infection. Gram-negative bacteria and anaerobes, such as Clostridia, are more often implicated in Fournier gangrene. This is a subtype of Type I infections affecting the groin and perianal areas. Clostridia account for 10% of overall Type I infections and typically cause a specific kind of necrotizing fasciitis known as gas gangrene or myonecrosis. Type II infection: This infection accounts for 20–30% of cases, mainly involving the extremities. This involves Streptococcus pyogenes, alone or in combination with staphylococcal infections. Methicillin-resistant Staphylococcus aureus (MRSA) is involved in up to a third of Type II infections. Infection by either type of bacteria can progress rapidly and manifest as shock. Type II infection more commonly affects young, healthy adults with a history of injury. Type III infection: Vibrio vulnificus is a bacterium found in saltwater. It occasionally causes NF after entering the body through a break in the skin. One in three patients with a V. vulnificus infection develop necrotizing fasciitis.
Individual quick freezing is a descriptive term that includes all forms of freezing that is "individual" (not in a whole block) and "quick" (taking a maximum of several minutes). It may correspond to cryogenic freezing, fluidized bed freezing, or any other technique that meets the definition.
=== Expansion and acquisition === By 1997, Reddy's made the transition from being an API and bulk drug supplier to regulated markets like the US and the UK, and a branded formulations supplier in unregulated markets like India and Russia, into producing generics, by filing an Abbreviated New Drug Application (ANDA) in the USA. The same year, Reddy's out-licensed a molecule for clinical trials to Novo Nordisk, a Danish pharmaceutical company. It strengthened its Indian manufacturing operations by acquiring American Remedies Ltd. in 1999. This acquisition made Reddy's the third largest pharmaceutical company in India, after Ranbaxy and Glaxo (I) Ltd., with a full spectrum of pharmaceutical products, which included bulk drugs, intermediates, finished dosages, chemical synthesis, diagnostics and biotechnology. Reddy's also started exploiting Para 4 filing as a strategy in bringing new drugs to the market at a faster pace. In 1999 it submitted a Para 4 application for omeprazole, the drug that had been the cornerstone of its success in India. In December 2000, Reddy's had undertaken its first commercial launch of a generic product in the US, and its first product with market exclusivity was launched there in August 2001. The same year, it also became the first non-Japanese pharmaceutical company from the Asia-Pacific region to obtain a New York Stock Exchange listing. In 2001 Reddy's became the first Indian company to launch the generic drug, fluoxetine (a generic version of Eli Lilly and Company’s Prozac) with 180-day market exclusivity in the USA.
=== Research === Chitosan and derivatives have been developed for their potential use in nanomaterials, bioadhesives, wound dressing materials, drug delivery systems, enteric coatings, and in medical devices. For example, chitosan nanoparticles produced using sodium tripolyphosphate as crosslinker are stable and biocompatible enough to be used as drug delivery materials.
Sources: en.wikipedia.org
=== Chemical lysis === This method uses chemical disruption. It is the most popular and simple approach. Chemical lysis chemically deteriorates/solubilizes the proteins and lipids present within the membrane of targeted cells. Common lysis buffers contain sodium hydroxide (NaOH) and sodium dodecyl sulfate (SDS). Cell lysis is best done at a pH range of 11.5–12.5. Although simple, it is a slow process, taking anywhere from 6 to 12 hours.
The volatilities for niobium and tantalum were similar within error limits, but dubnium appeared to be significantly less volatile. It was postulated that traces of oxygen in the system might have led to formation of DbOBr3, which was predicted to be less volatile than DbBr5. Later experiments in 1996 showed that group 5 chlorides were more volatile than the corresponding bromides, with the exception of tantalum, presumably due to formation of TaOCl3. Later volatility studies of chlorides of dubnium and niobium as a function of controlled partial pressures of oxygen showed that formation of oxychlorides and general volatility are dependent on concentrations of oxygen. The oxychlorides were shown to be less volatile than the chlorides. In 2004–05, researchers from Dubna and Livermore identified a new dubnium isotope, 268Db, as a fivefold alpha decay product of the newly created element 115. This new isotope proved to be long-lived enough to allow further chemical experimentation, with a half-life of over a day. In the 2004 experiment, a thin layer with dubnium was removed from the surface of the target and dissolved in aqua regia with tracers and a lanthanum carrier, from which various +3, +4, and +5 species were precipitated on adding ammonium hydroxide. The precipitate was washed and dissolved in hydrochloric acid, where it converted to nitrate form and was then dried on a film and counted.
== Sexual reproduction == The evolution of sexual reproduction may be a primordial and fundamental characteristic of eukaryotes, including single cell eukaryotes. Based on a phylogenetic analysis, Dacks and Roger proposed that facultative sex was present in the common ancestor of all eukaryotes. Hofstatter and Lehr reviewed evidence supporting the hypothesis that all eukaryotes can be regarded as sexual, unless proven otherwise. Sexual reproduction may have arisen in early protocells with RNA genomes (RNA world). Initially, each protocell would likely have contained one RNA genome (rather than multiple) since this maximizes the growth rate. However, the occurrence of damages to the RNA which block RNA replication or interfere with ribozyme function would make it advantageous to fuse periodically with another protocell to restore reproductive ability. This early, simple form of genetic recovery is similar to that occurring in extant segmented single-stranded RNA viruses (see influenza A virus). As duplex DNA became the predominant form of the genetic material, the mechanism of genetic recovery evolved into the more complex process of meiotic recombination, found today in most species. It thus appears likely that sexual reproduction arose early in the evolution of cells and has had a continuous evolutionary history.
Chromatography can be used to determine the presence of substances in a sample, as different components in a mixture have different tendencies to adsorb onto the stationary phase or dissolve in the mobile phase. Thus, different components of the mixture move at different speeds. Different components of a mixture can therefore be identified by their respective Rƒ values, which is the ratio between the migration distance of the substance and the migration distance of the solvent front during chromatography. In combination with the instrumental methods, chromatography can be used in the quantitative determination of substances. There are different types of chromatography that differ from the media they use to separate the analyte and the sample. In thin-layer chromatography, the analyte mixture moves up and separates along the coated sheet under the volatile mobile phase. In gas chromatography, the gas phase separates the volatile analytes. A common method of chromatography using liquid as a mobile phase is high-performance liquid chromatography.
By late 2018, Syrian opposition rebel groups were forced into Idlib Governorate, the last rebel-held governorate of Syria after seven years of fighting against the Assad regime and Syrian Army during the Syrian civil war, after the SAA captured the city of Aleppo and conducted peace deals with rebel groups in the southern Daraa Governorate. Several rebel groups were present in Idlib, including the Islamist rebel group Hay'at Tahrir al-Sham (which broke away from the Al-Nusra Front), the Turkish-backed Syrian National Army, and dozens of smaller nationalist and Islamist opposition groups which largely operate in a shared command with larger groups. In Southern Syria, the opposition consisted mostly of demobilised fighters who had undergone reconciliation through previous cease-fire agreements and subsequently conducted local insurrections as Government forces withdrew in early December. An additional American-backed Syrian Free Army opposition force controlled a section of desert around the post of al-Tanf. Between the end of the ceasefire and the start of the 2024 Syrian opposition offensives HTS leader Ahmed al-Sharaa sought peace deals with the other rebel coalitions, and hunted down Hurras al-Din and Islamic State fighters in rebel-held areas. Jolani also built institutions to digitize the rebel-held area, such as improving tax collecting, street cleaning, and food distribution, while preaching a message of unity to Syrian Christians and Shias.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.